Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
A 76-year-old woman presented to the emergency department after seeing blood in her urine. She explained that this had been going on since the previous day, when she also began to experience episodes ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results